Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis

Journal of Laboratory and Clinical Medicine

Volumn 138, Issue 1, 2001, Pages 22-31

  Visentin, Gian Paolo ^a,b,c   Moghaddam, Michael ^a,b,c   Beery, Sheila E ^a,b,c   McFarland, Janice G ^a,b,c   Aster, Richard H ^a,b,c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b Genetic Testing Institute Inc   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034962770     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2001.115525     Document Type: Article

References (38)

1. Heparin-induced thrombocytopenia
2. Interaction of heparin with platelets, including heparin-induced thrombocytopenia
3. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
4. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
5. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
6. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
7. Heparin-induced thrombocytopenia: Molecular pathogenesis
8. Heparin-induce thrombocytopenia: Towards consensus
9. Heparin-induced thrombocytopenia: Diagnostic tests and biological mechanisms
10. A diagnostic test for heparin-induced thrombocytopenia
11. Characterization of the humoral immune response in heparin-induced thrombocytopenia
12. Development of a flow cytometric assay for the laboratory diagnosis of heparin induced thrombocytopenia
13. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
14. Mode of interaction between platelet factor 4 and heparin
15. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
16. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia
17. Antibodies to macromolecular platelet factor 4 heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases
18. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG synthesis that induces thromboxane synthesis and platelet aggregation
19. Heparin-induced thrombocytopenia
20. Clinical usefulness of testing for a heparin-dependent platelet aggregating factor in patients with suspected heparin-associated thrombocytopenia
21. Heparin-induced thrombocytopenia: Laboratory studies
22. A diagnostic test for heparin-induced thrombocytopenia: Detection of platelet microparticles using flow cytometry
23. General physical properties of heparin
24. The 3-dimensional structure of bovine platelet factor 4 at 3.0 A resolution
25. Crystal structure of recombinant human platelet factor 4
26. Heparin-associated thrombocytopenia: The antibody is not heparin specific
27. Molecular distribution and statistical thermodinamics
28. Alkenes
29. The interaction of platelet factor 4 and glycosaminoglycans
30. A model of the platelet factor 4 complex with heparin
31. NMR solution structure of the 32-kd platelet factor 4 ELR-motif N-terminal chimera: A symmetric tetramer
32. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: Arginine residues are crucial for binding
33. Defining an antigenic epitopes on platelet factor 4 associated with heparin-induced thrombocytopenia
34. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis (HITT) recognize diverse epitopes on PF4: Heparin complexes
35. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium
36. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management
37. Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors
38. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis